Cancer immunotherapy using virus particles

A technology of virus particles and virus-like particles, applied in the direction of viruses, viral peptides, viruses/phages, etc.

Active Publication Date: 2017-08-01
CASE WESTERN RESERVE UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The mechanistic basis for immune regulation by any VLP is unknown, but some VLPs may have more capacity than others

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer immunotherapy using virus particles
  • Cancer immunotherapy using virus particles
  • Cancer immunotherapy using virus particles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: In situ vaccination with plant-derived viroid nanoparticle immunotherapy inhibits metastatic cancer

[0060] Current therapies are often ineffective against metastatic cancer, and emerging immunotherapies, while promising, are in the early stages of development. In situ vaccination refers to a process in which an immunostimulatory agent applied directly to the tumor alters the immunosuppressive microenvironment so that the immune system can respond efficiently to the tumor. The inventors hypothesized that treatment of lung tumor-bearing mice with viroid nanoparticles could modulate the immune environment of the lung and prevent metastatic injury of the B 16F10 class. This example shows that inhalation of self-assembled virus-like particles derived from cowpea mosaic virus (CPMV) inhibits tumor development in the lungs of mice following intravenous challenge. The inconsistency in tumor burden between CPMV- and PBS-treated mice was prominent and due to the p...

Embodiment 2

[0105] Example 2: eCPMV Treatment of Skin B16F10 Induces Systemic Anti-Tumor Immunity

[0106] like Image 6 As shown, the inventors established skin melanoma tumors, and injected eCPMV particles directly into the skin (100 μg / injection, arrows indicate injection days). The above treatment resulted in the complete disappearance of tumors in half of the mice. In cured mice, we then waited 4 weeks and challenged again with the same tumor cells, but we injected tumor cells on the opposite flank. The majority of these mice did not develop secondary tumors. For clarity, primary tumors were injected directly with particles, while mice bearing secondary tumors were left untreated. They must rely on a separate systemic antitumor immune memory. eCPMV was applied locally in the primary tumor, but systemic immunity was induced. "Re-challenged" mice that previously had B 16F10 skin tumors were injected directly, and shrunk and disappeared.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method of treating cancer in a subject in need thereof is described that includes administering a therapeutically effective amount of a virus or virus-like particle to the subject, wherein the virus particle is nonreplicating and noninfectious in the subject. The method represents a type of in situ vaccination, in which application of an immunostimulatory reagent directly to the tumor modifies the tumor microenvironment so that the immune system is able to respond to the tumor.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Patent Application Serial No. 62 / 076,543, filed November 7, 2014, U.S. Provisional Patent Application Serial No. 62 / 107,617, filed January 26, 2015, U.S. Provisional Patent Application Serial No. 62 / 107,617, filed May 11, 2015 Priority to Provisional Patent Application Serial No. 62 / 159,389, the contents of all of which are hereby incorporated by reference. [0003] A statement about federally funded research [0004] This invention is made under NIH Training Grant No. 5T32AI007363-22, NIH Training Grant No. T32HL105338, and Grant No. NIH1U54CA151662 awarded by the National Institutes of Health, and under Grant No. CMMI1333651 awarded by the National Science Foundation. Done with support. Background technique [0005] Metastatic cancers have the same poor prognosis regardless of tissue origin. Traditional chemotherapy and radiation therapy are largely ineffective for advanced d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/005C12N15/86C07H17/02
CPCA61K2039/5258A61K2039/544A61K2039/585C12N2770/32034C12N2770/32023C12N2770/32071C12N7/00C12N2770/32022A61K39/12A61P35/04A61P35/00A61K31/704A61K35/76Y02A50/30C12N2770/00023C12N2770/00034C12N2770/00071
Inventor N·F·斯坦梅茨A·M·文S·菲林P·H·利佐特
Owner CASE WESTERN RESERVE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap